Women | Men | |||||
HR* | 95% CI | P value | HR* | 95% CI | P value | |
Any cardiovascular event | n=96 | n=129 | ||||
sST2 (univariable) | 1.80 | 1.30 to 2.49 | <0.001 | 1.19 | 0.90 to 1.56 | 0.223 |
Adjusted for age | 1.72 | 1.22 to 2.44 | 0.002 | 1.30 | 0.99 to 1.71 | 0.063 |
Adjusted for age and creatinine | 1.71 | 1.22 to 2.41 | 0.002 | 1.28 | 0.97 to 1.69 | 0.080 |
Adjusted for age and NT-proBNP | 1.49 | 1.04 to 2.12 | 0.029 | 1.16 | 0.89 to 1.51 | 0.274 |
Adjusted for age, NT-proBNP and creatinine | 1.48 | 1.04 to 2.11 | 0.029 | 1.18 | 0.89 to 1.55 | 0.248 |
Adjusted for age, rhythm and systemic ventricular function | 1.67 | 1.20 to 2.33 | 0.002 | 1.28 | 0.98 to 1.68 | 0.071 |
Adjusted for age, congenital diagnosis†, NYHA class and cardiac medication | 1.23 | 0.87 to 1.75 | 0.240 | 1.30 | 0.99 to 1.70 | 0.056 |
Adjusted for full model‡ | 1.26 | 0.89 to 1.79 | 0.190 | 1.28 | 0.97 to 1.69 | 0.076 |
Adjusted for full model‡ and NT-proBNP | 1.17 | 0.81 to 1.69 | 0.407 | 1.18 | 0.89 to 1.56 | 0.250 |
Death or heart failure | n=40 | n=29 | ||||
sST2 (univariable) | 2.72 | 1.67 to 4.44 | <0.001 | 1.47 | 0.81 to 2.65 | 0.201 |
Adjusted for age | 2.68 | 1.55 to 4.63 | <0.001 | 1.83 | 1.03 to 3.23 | 0.039 |
Adjusted for age and creatinine | 2.68 | 1.55 to 4.62 | <0.001 | 1.61 | 0.88 to 2.94 | 0.125 |
Adjusted for age and NT-proBNP | 2.03 | 1.12 to 3.69 | 0.020 | 1.18 | 0.69 to 2.00 | 0.547 |
Adjusted for age, NT-proBNP and creatinine | 2.04 | 1.12 to 3.71 | 0.020 | – § | – | – |
Analysis including all covariates (full model) was not performed for the secondary endpoint due to insufficient statistical power.
*HRs are expressed per twofold increase in sST2 level. P value of interaction between sex and sST2=0.047 (primary endpoint) and p=0.104 for secondary endpoint.
†Congenital diagnosis of arterial switch operation, aortic stenosis or aortic coarctation (0) versus tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or pulmonary arterial hypertension (1).
‡Adjusted for age, creatinine, sinus rhythm, systemic ventricular function, congenital diagnosis, NYHA class 2–3 and cardiac medication.
§Insufficient statistical power to perform analysis.
NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble suppression of tumourigenicity-2.